# Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.

> clinical trial · VERIFIED · 2026-08-03

Status: NOT_YET_RECRUITING · Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. · Condition: NSCLC (Advanced Non-small Cell Lung Cancer)

- Company: Shanghai Allink Biotherapeutics Co., Ltd.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07742956

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.